FDA Seeks Ideas to Speed Up Cheaper Generic Drugs
Published Date: 5/19/2025
Notice
Summary
The FDA is gearing up to renew the Generic Drug User Fee program for 2028-2032 and wants your thoughts! This affects drug makers who pay fees to help speed up generic drug reviews. They’re hosting a public meeting and asking for comments before making any changes, with new rules needed by September 2027 to keep things rolling smoothly.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
GDUFA reauthorization by Sept 2027
If you make generic drugs and pay FDA user fees, the FDA is preparing to reauthorize the Generic Drug User Fee program for fiscal years 2028 through 2032. To keep collecting those fees, new legislation must be enacted by the end of September 2027.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
Previous / Next Documents
Previous: 2025-08871 — South Atlantic Fishery Management Council; Public Meeting
The South Atlantic Fishery Management Council is holding a big week of meetings to talk about managing snapper, grouper, mackerel, cobia, shrimp, and ocean habitats. Fishermen, seafood lovers, and coastal communities should pay attention because these talks could lead to new rules that affect fishing seasons and limits. The public can join in during a special comment session, so now’s the time to have your say!
Next: 2025-08873 — Agency Information Collection Activities; Comment Request; Standard Job Corps Contractor Information Gathering; Correction
The Department of Labor fixed a mistake in a recent notice about collecting info from Job Corps contractors. They corrected the official control number to keep everything clear and on track. This update helps contractors and the public know the right details—no changes to timing or costs, just a quick fix!